/CHEOY
CHEOY Stock - Cochlear Limited
Healthcare|Medical - DevicesOTC
$85.20-0.47%
$0.40 (-0.47%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.30
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+273.8%upside
Target: $318.48
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CHEOY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$84.35 – $86.05
TARGET (TP)$318.50
STOP LOSS$78.38
RISK/REWARD1:34.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.46
52W High$105.60
52W Low$74.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.34B | $2.24B | $1.96B | $1.64B | $1.49B |
| Gross Profit | $1.73B | $1.67B | $1.47B | $1.23B | $1.08B |
| Gross Margin | 73.7% | 74.9% | 75.0% | 75.0% | 72.5% |
| Operating Income | $406.10M | $475.00M | $412.40M | $361.70M | $327.90M |
| Net Income | $388.90M | $356.80M | $300.60M | $289.10M | $326.50M |
| Net Margin | 16.6% | 16.0% | 15.4% | 17.6% | 21.9% |
| EPS | $2.97 | $2.72 | $2.29 | $2.20 | $2.47 |
Company Overview
Cochlear Limited provides implantable hearing solutions for adults and children worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
2
100%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish2 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 16th 2025 | Goldman | Initiation | Neutral | - |
| May 12th 2023 | Bernstein | Initiation | Market Perform | - |
| August 22nd 2022 | Citigroup | Downgrade | Neutral | - |
Earnings History & Surprises
CHEOYBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$1.68
Q3 2024
EPS Surprise History
Q4 20
No data
Q2 21
No data
Q4 21
No data
Q2 22
No data
Q4 22
No data
Q2 23
No data
Q1 24
No data
Q3 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 11, 2026 | — | — | — | — |
Q3 2025 | Aug 18, 2025 | — | — | — | — |
Q1 2025 | Feb 13, 2025 | — | — | — | — |
Q3 2024 | Aug 15, 2024 | — | $1.68 | — | — |
Q1 2024 | Feb 18, 2024 | — | $1.98 | — | — |
Q2 2023 | Jun 30, 2023 | — | $1.60 | — | — |
Q4 2022 | Dec 31, 2022 | — | $1.47 | — | — |
Q2 2022 | Jun 30, 2022 | — | $1.25 | — | — |
Q4 2021 | Dec 31, 2021 | — | $1.87 | — | — |
Q2 2021 | Jun 30, 2021 | — | $1.03 | — | — |
Q4 2020 | Dec 31, 2020 | — | $2.76 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-4.66 | — | — |
Q4 2019 | Dec 31, 2019 | — | $1.92 | — | — |
Q2 2019 | Jun 30, 2019 | — | $1.79 | — | — |
Q4 2018 | Dec 31, 2018 | — | $1.72 | — | — |
Q2 2018 | Jun 30, 2018 | — | $1.72 | — | — |
Q4 2017 | Dec 31, 2017 | — | $1.48 | — | — |
Q2 2017 | Jun 30, 2017 | — | $1.49 | — | — |
Q4 2016 | Dec 31, 2016 | — | $1.40 | — | — |
Q2 2016 | Jun 30, 2016 | — | $1.24 | — | — |
Latest News
Envoy Medical Announces Its Pivotal Clinical Trial For Acclaim Cochlear Implant Reaches Midway Point Of Study's Full Enrollment Program
➖ NeutralBenzinga•Dec 18, 2025, 01:12 PM•Also:
Envoy Medical Issued Australian Patent No. 2022229818 Titled "Cochlear Implant System With Improved Input Signal-To-Noise Ratio"
📈 PositiveBenzinga•Dec 16, 2025, 01:14 PM•Also:
Envoy Medical Announces Completion Of First Set Of Activations In Final Stage Of Pivotal Clinical Study For Investigational Fully Implanted Acclaim Cochlear Implant
📈 PositiveBenzinga•Dec 10, 2025, 01:11 PM•Also:
Envoy Medical Says All 10 Patients In First Stage Of Acclaim Cochlear Implant Clinical Trial Have Completed Six-Month Follow Up Visits
📈 PositiveBenzinga•Nov 18, 2025, 01:02 PM•Also:
Envoy Medical Enrolls First Three Participants In Final Stage In Pivotal Clinical Study Of Full Implanted Acclaim Cochlear Implant
📈 PositiveBenzinga•Nov 4, 2025, 01:11 PM•Also:
Envoy Medical shares are trading higher after the company announced it received FDA approval to expand its clinical trial for the fully implanted Acclaim cochlear implant to the final stage based on 3-month data from the first 10 patients
📈 PositiveBenzinga•Oct 7, 2025, 03:39 PM•Also:
EXCLUSIVE: Envoy Medical Tells Benzinga Co. Received FDA Approval To Expand Its Clinical Trial For The Fully Implanted Acclaim Cochlear Implant To The Final Stage Based On 3-Month Data From The First 10 Patients
📈 PositiveBenzinga•Oct 7, 2025, 11:45 AM•Also:
Envoy Medical Announces It Is Scaling Its Commercialization Planning For The Company's Breakthrough Investigational Acclaim Fully Implanted Cochlear Implant As Pivotal Trial Progresses
📈 PositiveBenzinga•Sep 24, 2025, 12:03 PM•Also:
Envoy Medical Secures European Patent for Fully Implanted Cochlear System, Strengthening IP Ahead of Acclaim Launch
📈 PositiveBenzinga•Sep 19, 2025, 12:06 PM•Also:
Envoy Medical Reports Safety Milestone In Pivotal Trial For Fully Implanted Cochlear Implant, Remains On Track For FDA Submission
📈 PositiveBenzinga•Sep 3, 2025, 12:13 PM•Also:
Frequently Asked Questions about CHEOY
What is CHEOY's current stock price?
Cochlear Limited (CHEOY) is currently trading at $85.20 per share. The stock has moved -0.47% today.
What is the analyst price target for CHEOY?
The average analyst price target for CHEOY is $318.50, based on 1 analyst.
What sector is Cochlear Limited in?
Cochlear Limited operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the OTC exchange.
What is CHEOY's market cap?
Cochlear Limited has a market capitalization of $11.15 billion, making it a large-cap company.
Does CHEOY pay dividends?
No, Cochlear Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALBBY
Alibaba Health Information Technology Limited
$13.54
Mkt Cap: $10.9B
BDUUY
Bangkok Dusit Medical Services Public Company Limited
$32.33
Mkt Cap: $12.8B
CHJTF
CSPC Pharmaceutical Group Limited
$0.95
Mkt Cap: $10.9B
ERFSF
Eurofins Scientific SE
$74.21
Mkt Cap: $13.2B
FSPKF
Fisher & Paykel Healthcare Corporation Limited
$19.01
Mkt Cap: $11.1B
SONVF
Sonova Holding AG
$252.58
Mkt Cap: $15.1B
SONVY
Sonova Holding AG
$51.67
Mkt Cap: $15.4B
SSSGY
Sartorius AG
$43.34
Mkt Cap: $15.0B
WILLF
Demant A/S
$33.20
Mkt Cap: $7.0B
WILYY
Demant A/S
$16.46
Mkt Cap: $7.0B
Explore stocks similar to CHEOY for comparison